Global medical technology company MGC Diagnostics yesterday announced that its new trading symbol, “MGCD,” became effective. In connection with a recent name change, the company’s common stock has been assigned a new CUSIP number, 552768103. Outstanding stock certificates have not been affected by the name change and do not need to be exchanged.
MGC Diagnostics has launched a new corporate Web site and logo as part of a company-wide rebranding initiative. The new identity is intended to better communicate to customers and shareholders what the company brings to the market: leading-edge cardiorespiratory diagnostic technology, a renewed dedication to product innovation, customer service and support that are unmatched, and an aim at anticipating and solving unmet needs. The three vertical elements in the company’s new logo represent MGC Diagnostics’ pillars of commitment: Provide unmatched service and support; relentlessly make improvements; and anticipate and solve unmet customer needs. The circle around the pillars represents the company’s market, as MGC Diagnostics considers everyone who interacts with, uses, or benefits from the company’s products to be a customer.
Designing a differentiated position in the minds of stakeholders, customers, and competitors has been a guiding element of MGC Diagnostics’ strategy. The company has historically operated with three separate identities: Angeion for the investment community, New Leaf in the fitness business, and MEDGRAPHICS in the cardiorespiratory business. Of the three entities, MEDGRAPHICS has commanded the strongest identity and value position.
The company will execute a public launch of its new corporate identity at the European Respiratory Society (ERS) Annual Congress 2012 in Vienna, Austria. The ERS, which takes place Sept. 1-5 this year, is the biggest international gathering of respiratory professionals, who come together to learn about the most current scientific developments, cardiorespiratory technology innovations, newly released products, clinical practice, and patient care.
MGC Diagnostics is a worldwide medical technology company dedicated to cardiorespiratory health solutions. The company is engaged in developing, manufacturing, and marketing noninvasive diagnostics systems. MGC Diagnostics’ portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The company’s products are sold internationally through distributors and in the U.S. through a direct sales force, which targets heart and lung specialists in hospitals, university-based medical centers, medical clinics, physician offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations.
For more information, visit the company’s new corporate Web site at www.MGCDiagnostics.com
Let us hear your thoughts below: